Preimplantation Genetic Testing (PGT-A): Improving Success Rates in Advanced Maternal Age

In recent decades, many women have chosen to delay childbearing due to educational, professional, financial, and personal reasons. Although this shift has provided greater reproductive autonomy, advancing maternal age remains one of the most significant factors influencing fertility and pregnancy outcomes.

Women of advanced maternal age, commonly defined as 35 years and older, often experience reduced fertility, lower implantation rates, and an increased risk of miscarriage. One major reason for these outcomes is the rising prevalence of chromosomal abnormalities in embryos.

Preimplantation Genetic Testing for Aneuploidy (PGT-A) has emerged as an important tool in assisted reproductive medicine. By identifying embryos with the correct number of chromosomes before transfer, PGT-A may improve embryo selection and optimize IVF outcomes in selected patients.

This article explores the scientific basis, clinical applications, benefits, limitations, and role of Preimplantation Genetic Testing (PGT-A) in women of advanced maternal age.

Understanding Advanced Maternal Age and Fertility

Female fertility naturally declines with age.

Women are born with a finite number of oocytes, and both the quantity and quality of these eggs decrease over time.

Age-related reproductive changes include:

• Reduced ovarian reserve
• Decreased oocyte quality
• Lower implantation rates
• Increased miscarriage risk
• Higher incidence of chromosomal abnormalities

Although many women successfully conceive after age 35, reproductive outcomes generally decline with advancing age.

What Is Aneuploidy?

Aneuploidy refers to the presence of an abnormal number of chromosomes within a cell.

Humans normally possess:

• 46 chromosomes
• 23 inherited from the mother
• 23 inherited from the father

Embryos may develop chromosomal abnormalities when errors occur during cell division.

Examples include:

• Extra chromosomes
• Missing chromosomes

Common chromosomal abnormalities include:

• Trisomy 21 (Down syndrome)
• Trisomy 18
• Trisomy 13
• Monosomy X

The likelihood of embryonic aneuploidy increases significantly with maternal age.

Why Does Maternal Age Increase Aneuploidy Risk?

As women age, oocytes remain arrested in meiosis for prolonged periods.

Age-related biological changes may contribute to:

• Spindle apparatus dysfunction
• Chromosomal segregation errors
• Mitochondrial dysfunction
• DNA damage accumulation

These changes increase the probability that embryos will contain abnormal chromosome numbers.

Consequently, older women often experience:

• Lower pregnancy rates
• Higher miscarriage rates
• Increased risk of chromosomal disorders

What Is Preimplantation Genetic Testing for Aneuploidy (PGT-A)?

PGT-A is a laboratory procedure performed during an IVF cycle to evaluate embryos for chromosomal abnormalities before transfer.

The primary objective of PGT-A is to identify embryos with a normal chromosomal complement, known as euploid embryos.

Embryos identified as euploid may possess greater implantation potential and a lower risk of miscarriage.

How Is PGT-A Performed?

PGT-A involves several sequential steps.

Step 1: IVF and Embryo Development

Women undergo controlled ovarian stimulation followed by egg retrieval.

Retrieved oocytes are fertilized in the laboratory using:

• Conventional IVF
• Intracytoplasmic sperm injection (ICSI)

Embryos are cultured until the blastocyst stage.

Step 2: Embryo Biopsy

At the blastocyst stage, embryologists remove a small number of cells from the trophectoderm, the portion that later forms the placenta.

The inner cell mass, which develops into the fetus, is left undisturbed.

Step 3: Genetic Analysis

Biopsied cells undergo chromosomal analysis using advanced genetic technologies.

Common methods include:

• Next-generation sequencing (NGS)
• Array comparative genomic hybridization (aCGH)

These techniques evaluate all chromosomes simultaneously.

Step 4: Embryo Cryopreservation

Because genetic analysis requires time, embryos are usually frozen after biopsy.

Subsequently, a chromosomally normal embryo is selected for transfer during a later cycle.

Benefits of PGT-A in Advanced Maternal Age

PGT-A offers several potential advantages.

Improved Embryo Selection

PGT-A allows clinicians to prioritize embryos with normal chromosome numbers.

This may increase the likelihood of successful implantation.

Reduced Miscarriage Risk

Chromosomal abnormalities are a leading cause of early pregnancy loss.

Transfer of euploid embryos may lower miscarriage rates.

Enhanced IVF Efficiency

By selecting embryos with greater developmental potential, PGT-A may reduce the number of unsuccessful embryo transfers.

Single Embryo Transfer Support

Improved embryo selection facilitates elective single embryo transfer, reducing the risk of multiple pregnancies.

Potential Impact on IVF Success Rates

Several studies suggest that PGT-A may improve reproductive outcomes in selected populations, particularly women of advanced maternal age.

Potential benefits include:

• Higher implantation rates
• Increased clinical pregnancy rates
• Reduced miscarriage rates
• Shorter time to pregnancy

However, outcomes vary depending on patient characteristics and clinical circumstances.

Limitations of PGT-A

Despite its promise, PGT-A has important limitations.

Not All Embryos Are Suitable for Biopsy

Some embryos may fail to reach the blastocyst stage or may not survive culture.

Mosaicism

Embryos may contain a mixture of normal and abnormal cells, a phenomenon known as mosaicism.

Mosaic results can complicate interpretation and clinical decision-making.

Additional Costs

PGT-A increases IVF treatment expenses, which may limit accessibility for some patients.

No Guarantee of Pregnancy

Even chromosomally normal embryos may fail to implant.

Successful pregnancy also depends on:

• Endometrial receptivity
• Maternal health
• Uterine factors

Who May Benefit Most from PGT-A?

PGT-A may be particularly beneficial for:

• Women of advanced maternal age
• Patients with recurrent pregnancy loss
• Couples with repeated IVF failure
• Individuals seeking elective single embryo transfer

Clinical recommendations should always be individualized.

Ethical Considerations

The use of genetic testing in reproductive medicine raises important ethical considerations.

Areas of discussion include:

• Embryo selection decisions
• Accessibility and equity
• Genetic information privacy
• Informed consent

Comprehensive counseling is essential before undergoing PGT-A.

Counseling and Shared Decision-Making

Patients considering PGT-A should receive detailed counseling regarding:

• Potential benefits
• Limitations
• Expected outcomes
• Financial implications

Shared decision-making enables patients to make informed reproductive choices.

Future Directions in PGT-A

Advances in reproductive genetics continue to refine embryo assessment.

Emerging developments include:

• Improved sequencing technologies
• Non-invasive embryo testing
• Artificial intelligence-assisted embryo selection
• Enhanced mosaic embryo interpretation

These innovations may further improve reproductive outcomes in the future.

Conclusion

Preimplantation Genetic Testing for Aneuploidy (PGT-A) represents an important advancement in reproductive medicine, particularly for women of advanced maternal age. By identifying chromosomally normal embryos before transfer, PGT-A may improve embryo selection, reduce miscarriage risk, and enhance IVF efficiency in appropriately selected patients.

Although PGT-A does not guarantee pregnancy and may not benefit every patient, individualized treatment planning and thorough counseling can help couples make informed decisions regarding fertility care. As reproductive genetics continues to evolve, PGT-A is expected to remain a valuable component of personalized IVF treatment strategies.